Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hilda Garay

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Analytical and Bioanalytical Chemistry|August 3, 2021
Synthesis, LC-MS/MS analysis, and biological evaluation of two vaccine candidates against ticks based on the antigenic P0 peptide from R. sanguineus linked to the p64K carrier protein from Neisseria meningitidisLuis Javier González, Pedro E Encinosa Guzmán, Wendy Machado, et al.
Pathogens (Basel, Switzerland)|July 8, 2020
Functional and Mass Spectrometric Evaluation of an Anti-Tick Antigen Based on the P0 Peptide Conjugated to Bm86 ProteinAlina Rodríguez Mallón, Luis Javier González, Pedro Enrique Encinosa Guzmán, et al.
Biomolecules|June 2, 2021
Antimicrobial Activity of Cyclic-Monomeric and Dimeric Derivatives of the Snail-Derived Peptide Cm-p5 against Viral and Multidrug-Resistant Bacterial StrainsMelaine González-García, Fidel Morales-Vicente, Erbio Díaz Pico, et al.
Molecular and Cellular Biochemistry|July 8, 2011
CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical researchSilvio E Perea, Idania Baladron, Yanelda Garcia, et al.
Molecular and Cellular Biochemistry|June 26, 2008
CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivoSilvio E Perea, Osvaldo Reyes, Idania Baladron, et al.
Frontiers in Oncology|March 13, 2019
Safety and Therapeutic Profile of a GnRH-Based Vaccine Candidate Directed to Prostate Cancer. A 10-Year Follow-Up of Patients Vaccinated With HeberprovacJesús A Junco, Ranfis Rodríguez, Franklin Fuentes, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Analytical and Bioanalytical Chemistry|August 3, 2021
Synthesis, LC-MS/MS analysis, and biological evaluation of two vaccine candidates against ticks based on the antigenic P0 peptide from R. sanguineus linked to the p64K carrier protein from Neisseria meningitidisLuis Javier González, Pedro E Encinosa Guzmán, Wendy Machado, et al.
Pathogens (Basel, Switzerland)|July 8, 2020
Functional and Mass Spectrometric Evaluation of an Anti-Tick Antigen Based on the P0 Peptide Conjugated to Bm86 ProteinAlina Rodríguez Mallón, Luis Javier González, Pedro Enrique Encinosa Guzmán, et al.
Biomolecules|June 2, 2021
Antimicrobial Activity of Cyclic-Monomeric and Dimeric Derivatives of the Snail-Derived Peptide Cm-p5 against Viral and Multidrug-Resistant Bacterial StrainsMelaine González-García, Fidel Morales-Vicente, Erbio Díaz Pico, et al.
Molecular and Cellular Biochemistry|July 8, 2011
CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical researchSilvio E Perea, Idania Baladron, Yanelda Garcia, et al.
Molecular and Cellular Biochemistry|June 26, 2008
CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivoSilvio E Perea, Osvaldo Reyes, Idania Baladron, et al.
Frontiers in Oncology|March 13, 2019
Safety and Therapeutic Profile of a GnRH-Based Vaccine Candidate Directed to Prostate Cancer. A 10-Year Follow-Up of Patients Vaccinated With HeberprovacJesús A Junco, Ranfis Rodríguez, Franklin Fuentes, et al.
Pageof 4